MedTrace Logo

VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection

NCT03906474 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-04-08

No results posted yet for this study

Summary

This is a clinical study to assess the safety of primary, secondary and tertiary blood-stage controlled human Plasmodium falciparum malaria infection of healthy malaria-naïve UK adults, as well as to evaluate any effect of prior exposure to a blood-stage controlled human malaria infection (CHMI) on the parasite multiplication rate.

As a secondary objective, the immune response to primary, secondary and tertiary P. falciparum blood-stage infection, as well as gametocytaemia, will also be assessed.

Conditions

Interventions

BIOLOGICAL

Blood-stage controlled human P. falciparum malaria infection

Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela M Minassian, MBBS MA DPhil MRCP FRCPath · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-06
Primary Completion
2019-02-14
Completion
2019-02-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03906474 on ClinicalTrials.gov